Public consultations will take place when there are any proposed new Regulations or amendments to existing Regulations including any proposed changes to the fees MHRA charges.
At the end of the exercise copies of all non-confidential replies can be requested from our Information Centre, email info@mhra.gsi.gov.uk
Latest device consultations
-
19 Oct 2009 | Public consultation (RCX/004/002/042): MHRA regulatory fees for medical devices - proposals for 1 April 2010
This consultation seeks your views on proposals to change the levels of fees charged by the MHRA for our medical device regulatory activities covering notified bodies (NBs) and conformity assessment bodies (CABs).
-
15 Oct 2008 | Public consultation (RCX/004/002/039): MHRA regulatory fees for medical devices - proposals for 1 April 2009
Consultation RCX/004/002/039 sought your views on proposals to change the levels of fees charged by the MHRA for our medical device regulatory activities covering clinical investigations, notified bodies and conformity assessment bodies.
-
23 May 2008 | Public consultation on amendment to the Medical Devices Regulations 2002
This consultation seeks your views on proposed changes to the Medical Devices Regulations 2002 to transpose Directive 2007/47/EC which amends the medical devices and active implantable medical devices Directives.
-
16 Oct 2007 | Public consultation (RCX/004/002/036): MHRA regulatory fees for medical devices - proposals for 1 April 2008
Consultation RCX/004/002/036 seeks your views on proposals to change the levels of fees charged by the MHRA for our medical device regulatory activities covering clinical investigations (CIs), notified bodies (NBs) and conformity assessment bodies (cabs)
-
23 Nov 2006 | Public consultation (RCX/004/002/035): MHRA regulatory fees for medical devices - proposals for 1 April 2007
A public consultation was carried out between 21 November 2006 and 13 February 2007 on proposals to change the levels of fees charged by the MHRA for our medical device regulatory activities covering clinical investigations, notified bodies, and conformity assessment bodies. MHRA received responses from four organisations.
